Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Monthly Archives: May 2013
[Development of an adenovirus vector containing a hepatitis C virus expression cassette and its application].
Posted: May 25, 2013 at 6:25 am
Authors: Yoshida T, Kondoh M, Mizuguchi H, Yagi K
Abstract
Hepatitis C virus (HCV) is a hepatotropic member of the Flaviviridae family and contains a 9.6 kb positive-sense RNA genome. Approximately 170-million people are infected with HCV worldwide. These people face increased risks of chronic hepatitis, cirrhosis and hepatocellular carcinoma compared with the general population. Transduction of the HCV genome into hepatocytes is essential for understanding the mode of action of HCV infection, and for preparing HCV, evaluating HCV replication, and screening anti-HCV drugs. Although electroporation of in vitro-synthesized HCV genome and transduction of plasmid vectors containing the HCV genome are widely used in HCV research, a more convenient system with higher transduction efficie...
MedWorm Sponsor Message: Find the best Christmas presents and January Sales in the UK with this simple shopping directory.
Posted in Gene therapy
Comments Off on [Development of an adenovirus vector containing a hepatitis C virus expression cassette and its application].
Adult Stem Cells Anti Aging – Video
Posted: May 24, 2013 at 2:47 pm
Adult Stem Cells Anti Aging
The evolution of Jeunesse and the scientific breakthrough in Anti Aging using Adult Stem Cells. For more info visit: http://www.adultstemcellsantiaging.com or Like us on Facebook: http://on.fb.me/12irwrI.
By: HumanCellsAntiAging
Visit link:
Adult Stem Cells Anti Aging - Video
Posted in Stem Cell Videos
Comments Off on Adult Stem Cells Anti Aging – Video
Wow! Another source of fat stem cells – Video
Posted: May 24, 2013 at 2:47 pm
Wow! Another source of fat stem cells
http://www.stemcellsarthritistreatment.com A recent study by Koh and colleagues published in the journal Arthroscopy highlighted another source of stem cells...
By: Nathan Wei
Read the original:
Wow! Another source of fat stem cells - Video
Posted in Stem Cell Videos
Comments Off on Wow! Another source of fat stem cells – Video
Boy’s stem cells successfully treat cerebral palsy
Posted: May 24, 2013 at 10:49 am
Washington, May 24 (ANI): Doctors have been able to successfully treat a 2.5-year-old boy who had suffered from cardiac arrest and brain damage, putting him in a vegetative state, using his own cord blood containing stem cells.
The symptoms improved significantly; over the following months, the child learned to speak simple sentences and to move.
"Our findings, along with those from a Korean study, dispel the long-held doubts about the effectiveness of the new therapy", says Dr. Arne Jensen of the Campus Clinic Gynaecology. Together with his colleague Prof. Dr. Eckard Hamelmann of the Department of Paediatrics at the Catholic Hospital Bochum (University Clinic of the RUB), he reports in the journal "Case Reports in Transplantation".
At the end of November 2008, the child suffered from cardiac arrest with severe brain damage and was subsequently in a persistent vegetative state with his body paralysed. Up to now, there has been no treatment for the cause of what is known as infantile cerebral palsy. "In their desperate situation, the parents searched the literature for alternative therapies", Arne Jensen explains. "They contacted us and asked about the possibilities of using their son's cord blood, frozen at his birth."
Nine weeks after the brain damage, on 27 January 2009, the doctors administered the prepared blood intravenously. They studied the progress of recovery at 2, 5, 12, 24, 30, and 40 months after the insult. Usually, the chances of survival after such a severe brain damage and more than 25 minutes duration of resuscitation are six per cent. Months after the severe brain damage, the surviving children usually only exhibit minimal signs of consciousness. "The prognosis for the little patient was threatening if not hopeless", the Bochum medics say.
After the cord blood therapy, the patient, however, recovered relatively quickly. Within two months, the spasticity decreased significantly. He was able to see, sit, smile, and to speak simple words again. Forty months after treatment, the child was able to eat independently, walk with assistance, and form four-word sentences. "Of course, on the basis of these results, we cannot clearly say what the cause of the recovery is", Jensen says. "It is, however, very difficult to explain these remarkable effects by purely symptomatic treatment during active rehabilitation."
The study has been published in the journal "Case Reports in Transplantation". (ANI)
Here is the original post:
Boy's stem cells successfully treat cerebral palsy
Posted in Stem Cells
Comments Off on Boy’s stem cells successfully treat cerebral palsy
Discarded immune cells induce the relocation of stem cells
Posted: May 24, 2013 at 10:49 am
May 23, 2013 CNIC researchers have discovered that the daily clearance of neutrophils from the body stimulates the release of hematopoietic stem cells from the bone marrow into the bloodstream, according to a report published today in the journal Cell.
Neutrophils are leukocytes (white blood cells) that defend the body against attack from bacteria and other disease organisms. To perform their function, these cells release toxic substances when they come into contact with microorganisms. However, release of these substances in the wrong place by damaged neutrophils can result in severe injury to blood vessels and tissues. Evolution appears to have resolved this conflict by ensuring that neutrophils are renewed much more rapidly than most other cells in the body: approximately 1011 neutrophils are eliminated every day and an equivalent number of stem cells are released into the bloodstream. This in turn generates a second problem: what to do with all these cells that have to be eliminated.
Dr. Andrs Hidalgo and his team in the Department of Epidemiology, Atherosclerosis and Cardiovascular Imaging, led by Dr. Valentn Fuster, have discovered the function of these neutrophils expelled every day by the body.
Graduate student Mara Casanova Acebes (Universidad Autnoma de Madrid), found that when additional apoptotic neutrophils were injected into mice, there was an increase in the number of circulating hematopoietic stem cells, the cells that generate all blood cells.
Using a wide variety of experimental approaches, including imaging assays, pharmacological treatments and genetic analysis, the team showed that when neutrophils in the blood get old, they migrate to the bone marrow to be eliminated by specialized phagocytotic cells called macrophages. The act of phagocytosing the neutrophils alters these macrophages' genetic properties and functions, and these changes in turn alter the function of specialized cells whose job it is to retain hematopoietic stem cells in the bone marrow. "As a consequence, the stem cells are released into the blood," explains Mara Casanova, first author of the study.
According to Dr. Hidalgo, "Key questions that arise from our study relate to the role of the hematopoietic stems cells expelled from the bone marrow, and how the elimination of neutrophils might affect other important stem cell populations, for example those that produce tumors."
The research also reveals that the aging of neutrophils follows a day/night, or circadian, cycle, suggesting possible implications for disease processes -- for instance heart attack -- that occur more frequently at certain times of day.
"Our study shows that stem cells are affected by day/night cycles thanks to this cell recycling. It is possible that the malign stem cells that cause cancer use this mechanism to relocate, for example during metastasis," Hidalgo emphasizes.
But this finding could have more direct implications for cardiovascular health. According to the authors, the daily changes in the function of neutrophils could be responsible for the tendency of acute cardiovascular and inflammatory events, such as heart attack, sepsis or stroke, to occur at certain times of day.
Dr. Hidalgo concludes, "Given that this new discovery describes fundamental processes in the body that were unknown before, it will now be possible to interpret the alterations to certain physiological patterns that occur in many diseases."
The rest is here:
Discarded immune cells induce the relocation of stem cells
Posted in Stem Cells
Comments Off on Discarded immune cells induce the relocation of stem cells
Multimillion Dollar Carrots for Stem Cell Research in California
Posted: May 23, 2013 at 6:30 pm
Directors of the California stem cell
agency approved an $80 million business-friendly plan that will
dangle multimillion dollar carrots before biotech firms in an effort
to push therapies into the marketplace.
The upfront payment effort will allow
CIRM to take part in early stage clinical trials at no risk and could
generate a list of achievements that will be useful in creating
support for fresh funding after CIRM's money runs out in 2017.
CIRM to take part in early stage clinical trials at no risk and could
generate a list of achievements that will be useful in creating
support for fresh funding after CIRM's money runs out in 2017.
The proposal is the first-ever from
CIRM that involves no upfront payments. Instead, recipients will have
to meet agreed-upon criteria to receive either grants or loans.
CIRM that involves no upfront payments. Instead, recipients will have
to meet agreed-upon criteria to receive either grants or loans.
A CIRM staff document said,
“The major development milestone and
success criteria will be mutually agreed upon between CIRM and the
applicant at the beginning of the project(s) and at a minimum will
require completion of a clinical trial that shows some level of
biological activity/clinical efficacy and safety. The advantage to
CIRM of this...is that CIRM funds will only be applied to projects
that are successful.”
The proposal was wrapped into what the
agency calls its strategic partnership plan, which also has a more
conventional aspect, providing loans and grants in advance.
agency calls its strategic partnership plan, which also has a more
conventional aspect, providing loans and grants in advance.
As part of the program, the CIRM board
also today approved a $6.4 million award to Sangamo BioSciences of
Richmond, Ca., to help develop a therapy for
beta-thalassemia. The firm will have to match the amount of the
award.
also today approved a $6.4 million award to Sangamo BioSciences of
Richmond, Ca., to help develop a therapy for
beta-thalassemia. The firm will have to match the amount of the
award.
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Multimillion Dollar Carrots for Stem Cell Research in California
California Stem Cell Agency: 5 Percent Budget Increase for Coming Fiscal Year
Posted: May 23, 2013 at 4:27 pm
Directors of the California stem cell
agency today approved a $17.4 million operating budget for the fiscal
year beginning July 1, an increase of 5.1 percent over spending for
the current year.
As usual, the agency tries to portray
its budget as a decrease in spending. Directors were told that it
represented a 3 percent decline from the current year. However, the
comparison is not made to actual spending for this year. Instead, the
staff compares the 2013-14 budget to budget figures proposed last
May, which are now no more than time-worn ephemera.
its budget as a decrease in spending. Directors were told that it
represented a 3 percent decline from the current year. However, the
comparison is not made to actual spending for this year. Instead, the
staff compares the 2013-14 budget to budget figures proposed last
May, which are now no more than time-worn ephemera.
Most of the budget goes for salaries
and benefits ($12.2 million ) with outside contracting running next
($2 million). (See here for details.) The budget projects 59 employees for next year
compared to 57 currently. CIRM staff said the number of employees is expected to remain about
the same until 2017 or so when its workload is projected to diminish.
and benefits ($12.2 million ) with outside contracting running next
($2 million). (See here for details.) The budget projects 59 employees for next year
compared to 57 currently. CIRM staff said the number of employees is expected to remain about
the same until 2017 or so when its workload is projected to diminish.
The agency is expected to run out of
money for new grants in 2017, but it is working on a plan to develop
a combination of private and public funding to continue its work.
money for new grants in 2017, but it is working on a plan to develop
a combination of private and public funding to continue its work.
The spending plan reflects the cost of
overseeing about $1.8 billion in nearly 600 grants and loans plus
developing new research proposals that are likely to be funded in the
next few years. The operational budget is capped by law at 6 percent
of the amount of funds the agency distributes over its lifetime.
overseeing about $1.8 billion in nearly 600 grants and loans plus
developing new research proposals that are likely to be funded in the
next few years. The operational budget is capped by law at 6 percent
of the amount of funds the agency distributes over its lifetime.
Posted in Stem Cells, Stem Cell Therapy
Comments Off on California Stem Cell Agency: 5 Percent Budget Increase for Coming Fiscal Year
$36 Million Recruitment: Names of Researchers Being Lured to California
Posted: May 23, 2013 at 3:02 pm
Here are the names of the researchers being recruited to California by the California stem cell agency with $36 million in awards. The sixth asked not to be revealed since he/she has yet to tell the current institution and are in
negotiations with their new institution
· Hiromitsu
Nakauchi of the University of Tokyo, who would be moving to Stanford
University
Nakauchi of the University of Tokyo, who would be moving to Stanford
University
· Barry
R. Stripp of Duke moving to Cedars-Sinai Medical Center
R. Stripp of Duke moving to Cedars-Sinai Medical Center
· Richard
Gregory of Harvard and Children’s Hospital, Boston moving to UC
Santa Cruz
Gregory of Harvard and Children’s Hospital, Boston moving to UC
Santa Cruz
· Eric
Ahrens of Carnegie Mellon moving to UC San Diego
Ahrens of Carnegie Mellon moving to UC San Diego
Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/Kbc3TScH6ds/36-million-recruitment-names-of.html
Posted in Stem Cells, Stem Cell Therapy
Comments Off on $36 Million Recruitment: Names of Researchers Being Lured to California
Stem Cell Agency Approves $36 million to Recruit Six Scientists to California
Posted: May 23, 2013 at 2:34 pm
The California stem cell agency today
awarded $36 million to six scientists to lure them to the Golden
State, in what was the agency's largest-ever recruiting round.
The awards more than doubled the amount
of CIRM has spent on recruitment. Until today, the agency had awarded
only $23.2 million for four awards.
of CIRM has spent on recruitment. Until today, the agency had awarded
only $23.2 million for four awards.
Today's awards ranged from $7.5 million
to $4.8 million. The agency did not immediately identify the recipients. However, testimony at the meeting indicated that two of the institutions involved were UC San Francisco and the Gladstone Institute (the $7.5 million award) and UC Santa Cruz (a $5.4 million award). (The agency later released the list, which can be found here. Here is a link to the CIRM press release.)
to $4.8 million. The agency did not immediately identify the recipients. However, testimony at the meeting indicated that two of the institutions involved were UC San Francisco and the Gladstone Institute (the $7.5 million award) and UC Santa Cruz (a $5.4 million award). (The agency later released the list, which can be found here. Here is a link to the CIRM press release.)
The differences in the size of the awards had to do with the overhead charges that are levied by the institutions at which the scientists would work, CIRM staff said. The "direct costs" of the research for each grant was $4.5 million.
Six applications were considered in the
latest round, including one that was scored at 75 that was rejected by grant reviewers. However, CIRM staff recommended that application, which involved UC San Francisco and Gladstone, be funded. (See here and here.)
latest round, including one that was scored at 75 that was rejected by grant reviewers. However, CIRM staff recommended that application, which involved UC San Francisco and Gladstone, be funded. (See here and here.)
Previous winners of the recruitment awards were Robert Wechsler-Reya, Sanford-Burnham; Dennis Steindler,
The Parkinson's Institute; Andrew McMahon, USC, and Peter Coffey, UC
Santa Barbara.
The Parkinson's Institute; Andrew McMahon, USC, and Peter Coffey, UC
Santa Barbara.
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Stem Cell Agency Approves $36 million to Recruit Six Scientists to California
BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress
Posted: May 23, 2013 at 1:50 pm
BOTHELL, Wash., May 23, 2013 /PRNewswire/ --BioLife Solutions, Inc. (BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced its participation at the Terrapinn World Stem Cells & Regenerative Medicine Congress 2013 this week in London.
(Logo: http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)
Dr. Aby J. Mathew, BioLife's Senior Vice President and Chief Technology Officer, will make a presentation titled "Critical Stability and Biopreservation Considerations for Manufacturing, Storage and Clinical Delivery of Cell and Tissue Products," to the audience of executives and product development managers of commercial regenerative medicine companies. The presentation outlines the risk to clinical and commercial success of cell and tissue products due to stability limitations from the use of non-optimized storage, transport and cryopreservation freeze media. Comparative data illustrating the superior preservation efficacy of BioLife's HypoThermosol storage and shipping media, and CryoStor cryopreservation freeze media will be presented on relevant cell and tissue types.
Mike Rice, Chief Executive Officer, commented, "We continue to build traction in the high growth regenerative medicine market, and estimate that more than 65 percent of the presenting companies at this conference have adopted our best in class, clinical grade biopreservation media products. A key value-added service we provide, which directly translates into expanded product adoption, is the high quality consulting our team offers to prospective and current customers. Biopreservation outcomes such as cell and tissue shelf life, viability and recovery can greatly impact commercial potential. The combination of the efficacy and quality of our proprietary platform technology, along with our expert technical consulting services, is now recognized and highly valued in the development and commercialization of regenerative medicine products and therapies."
The regenerative medicine market is expected to grow to more than $35 billion by 2019, according to TriMark Publications' recently published "Regenerative MedicineMarkets" report. BioLife's addressable portion of the market is the demand for reagents used to store, ship and freeze source material and manufactured doses of cell-based products and therapies.
For a list of upcoming events, please visit http://biolifesolutions.com/cell-therapy/category/events/.
About BioLife Solutions
BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues. The Company's proprietary HypoThermosol and CryoStor platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce biopreservation-induced cell damage and death. BioLife's enabling technology provides academic and clinical researchers, and commercial companies significant improvements in post-thaw cell, tissue, and organ viability and function. For more information please visit http://www.biolifesolutions.com, and follow BioLife on Twitter.
This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Read more from the original source:
BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress
Posted in Regenerative Medicine
Comments Off on BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress
